Lincoln Pharmaceuticals Reports 31% Profit Growth and Expands Global Market Presence
Lincoln Pharmaceuticals reported a 30.89% increase in consolidated net profit to Rs 36.23 crore for the quarter ended June 2026, with sales rising 15.06% to Rs 177.28 crore compared to the same period last year. Profit before tax grew 34.36% to Rs 47.55 crore, and EBITDA increased by 32.29%. The company aims to reach Rs 1,000 crore in revenue within three years, expanding its presence in regulated and semi-regulated markets across over 60 countries, including recent entries into Canada and approvals in Australia and the EU.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 38/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 13 Aug, 08:54 am. Other outlets followed.
- 1businessstandard13 Aug, 08:54 amLincoln Pharmaceuticals consolidated net profit rises 30.89 in the June 2026 quarter
- 2businessstandard13 Aug, 09:37 amLincoln Pharma jumps after Q1 PAT climbs 31 YoY to Rs 36 cr
Who's involved
Institutions and figures named across source coverage.
Story context
- Category
- Business
- Location
- Canada
- Sources analysed
- 2
- Last analysed
- 13 Aug 2026
- Key entities
- Abraham LincolnCroreIndian rupeePharmaceutical industryTelecommunicationsLarsen & ToubroNvidiaRamaArtificial intelligenceIndiaMedicationDiabetes